Home » Stocks » ISEE

IVERIC bio, Inc. (ISEE)

Stock Price: $6.14 USD 0.13 (2.16%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 547.26M
Revenue (ttm) n/a
Net Income (ttm) -76.59M
Shares Out 92.68M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $6.14
Previous Close $6.01
Change ($) 0.13
Change (%) 2.16%
Day's Open 6.02
Day's Range 5.76 - 6.20
Day's Volume 463,602
52-Week Range 2.64 - 7.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)--IVERIC bio granted non-statutory stock options to purchase an aggregate of 28,000 shares of common stock to two newly hired, non-executive employees.

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced that Glenn P. Sblendorio, CEO and President, will present at the 39th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2021.

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--IVERIC bio granted a newly hired employee a non-statutory stock option to purchase 34,000 shares of the Company's common stock.

Seeking Alpha - 3 months ago

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2020 Results - Earnings Call Transcript

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced the financial and operating results for the fiscal quarter ended September 30, 2020 and provided a general business update.

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced today that the Company will participate in upcoming virtual investor conferences in November.

Insider Monkey - 4 months ago

Timothy P. Lynch's Stonepine Capital is a life science-focused hedge fund that seeks to utilize its industry experience to uncover undervalued and under-the-radar health companies. The fund ta...

Other stocks mentioned: CTIC, CERC, LGND
Business Wire - 4 months ago

NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced that it will report its third quarter 2020 financial and operating results on Monday, November 2, 2020.

Zacks Investment Research - 4 months ago

IVERIC bio (ISEE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced that the Company will participate in the two upcoming virtual investor conferences and a retina showcase conference in September.

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)--IVERIC bio granted two newly hired, non-executive employees a non-statutory stock option to purchase 34,000 shares of the Company’s common stock.

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)--IVERIC announced that the positive Phase 3 results from its GATHER1 clinical trial with Zimura® were published in Ophthalmology®.

Seeking Alpha - 6 months ago

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2020 Results - Earnings Call Transcript

Business Wire - 6 months ago

NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced the financial and operating results for the fiscal quarter ended June 30, 2020 and provided a general business update.

Business Wire - 6 months ago

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced Pravin Dugel, MD will present an overview of the Company at the Wedbush PacGrow Healthcare Virtual Conference on Aug. 12, 2020.

Business Wire - 6 months ago

NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced that it will report its second quarter 2020 financial and operating results on Wednesday, August 5, 2020.

Business Wire - 7 months ago

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced the election of Mark S. Blumenkranz, M.D.

Zacks Investment Research - 7 months ago

IVERIC bio, Inc. (ISEE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Seeking Alpha - 7 months ago

Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: RUBY, ZYNE
Seeking Alpha - 8 months ago

Iveric Bio: Pick Up Post-Fundraising Low And Hold For Good News

The Motley Fool - 8 months ago

An upsized public offering has investors increasingly confident about its prospects.

Benzinga - 8 months ago

Shares of New York-based biopharma IVERIC bio Inc (NASDAQ: ISEE) were advancing strongly Monday morning on the back of a positive clinical readout.

PRNewsWire - 8 months ago

NEW YORK, June 15, 2020 /PRNewswire/ -- IVERIC bio, Inc. (Nasdaq: ISEE) today announced positive 18 month results from the Company's first Phase 3 clinical trial (OPH2003) for Zimura® (avacinc...

Zacks Investment Research - 9 months ago

IVERIC bio (ISEE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 9 months ago

Top Ranked Momentum Stocks to Buy for May 13th

Other stocks mentioned: IDCC, MRSN, SLDB
Zacks Investment Research - 9 months ago

Top Ranked Momentum Stocks to Buy for May 12th

Other stocks mentioned: CHGG, CLLS, HEAR
Seeking Alpha - 9 months ago

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Investors need to pay close attention to IVERIC bio (ISEE) stock based on the movements in the options market lately.

Seeking Alpha - 11 months ago

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Iveric bio: Much More Upside Ahead

24/7 Wall Street - 1 year ago

After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in th...

Other stocks mentioned: CDMO, ENDP, IGMS, ILMN, KOD, MYL, NVCN, PCRX, PFE, XFOR
Benzinga - 1 year ago

Iveric Bio Inc’s (NASDAQ: ISEE) lead asset, Zimura, could begin a pivotal clinical study in the geographic atrophy market in the quarter, according to Wedbush.

InvestorPlace - 1 year ago

Although talking about stocks to sell typically elicits anger and negative emotions, this list is all about protecting your interests.

Other stocks mentioned: CLDR, DTSS, EROS, FCEL, MCF, SSI
The Motley Fool - 1 year ago

Seven biotechs led the way.

Other stocks mentioned: ARQL, AXSM, CNST, DRRX, EVER, KOD, PRVB, RCEL, SSI
Seeking Alpha - 1 year ago

IVERIC bio: Promising Data In GA, Valuation Still Cheap With Multiple Catalysts In 2020

Zacks Investment Research - 1 year ago

IVERIC bio (ISEE) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

IVERIC bio's (ISEE) third-quarter earnings improve year over year. The company plans to initiate a pivotal study on Zimura for treating GA early next year.

Seeking Alpha - 1 year ago

Iveric Bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.

Seeking Alpha - 1 year ago

Iveric Bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2019 Results - Earnings Call Transcript

GuruFocus - 1 year ago

Market indexes soared Wednesday as investors anticipate an interest rate cut ahead.

Other stocks mentioned: CWWBF, NVFY, TST

About ISEE

IVERIC bio, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration. It is also developing High temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company has a license agreement w... [Read more...]

Industry
Biotechnology
Founded
2007
CEO
David Guyer
Employees
55
Stock Exchange
NASDAQ
Ticker Symbol
ISEE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for IVERIC bio stock is "Strong Buy." The 12-month stock price forecast is 13.00, which is an increase of 111.73% from the latest price.

Price Target
$13.00
(111.73% upside)
Analyst Consensus: Strong Buy